Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
about
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachPonesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseasesLysophospholipids and their receptors in the central nervous systemExperimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrierFingolimod phosphate attenuates oligomeric amyloid β-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neuronsDiscovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitorsSynthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.Imaging Plasmodium immunobiology in the liver, brain, and lung.Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Isoflurane posttreatment reduces neonatal hypoxic-ischemic brain injury in rats by the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway.Gene expression profiles of patients with cerebral hematoma following spontaneous intracerebral hemorrhage.Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.Fingolimod for relapsing multiple sclerosis: an update.Levels of S100B are raised in female patients with schizophrenia.Oral disease-modifying therapies for multiple sclerosis.S1P is associated with protection in human and experimental cerebral malariaChemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic moleculesAKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple SclerosisOral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.Ceramide signaling in cancer and stem cells.A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes.FTY720 (fingolimod) for relapsing multiple sclerosis.The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis.Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in ratsDynamic Cross Talk between S1P and CXCL12 Regulates Hematopoietic Stem Cells Migration, Development and Bone RemodelingVascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammationApproaches to neuroprotective strategies in multiple sclerosis.Roles for lysophospholipid S1P receptors in multiple sclerosis.Emerging oral drugs for relapsing-remitting multiple sclerosis.Post-ischemic inflammation in the brain.Disease-specific therapy of idiopathic inflammatory demyelinating disorders.Immunobiology of Plasmodium in liver and brain.
P2860
Q22305854-EE46D49F-D3CA-4104-8DDD-65AE0F57AD3CQ26771821-D1F72A00-6217-4178-9EA8-82D9008F9FC4Q26859168-C6770200-2F94-4940-BE58-44B953681E7BQ27322655-71E6BC63-D0F8-4455-853D-A399E939C219Q28486184-28D4F2C6-269E-492A-8462-C1378E35EF4CQ30432733-3F452579-F937-4443-9209-9F6E41CA7B53Q30435057-43B5C5B4-E2A0-4DAF-8F9B-37C7C8C9624FQ30561036-99D27595-1161-4BDC-B97F-F38463C88B0CQ33611979-8F374395-5E10-4D3E-965B-F7BFE9024A8FQ33651898-81B87D3A-FCF6-47E0-9B28-A8007816A702Q33727962-26D0398D-A969-4A13-98A7-AD6E20FD9799Q33810559-55ABE558-77B2-49E1-909A-0A8AA8763AE6Q33881977-1B2BCEE2-304D-48FF-9F4B-EB7547EF83C4Q34049035-CD7615BE-54F2-406A-859E-7724C8AD1481Q34105212-53C89290-8980-4ABE-9DF9-B915676F6CB4Q34518822-6CB9C9D4-D1D9-48AE-87DA-5FE0FF38444DQ34618474-B7482AC6-516C-45BE-8822-AC60E0B72D70Q34738782-C0CFB3CB-DCD3-43E0-BCCF-907CB83D375EQ34996562-76BBEF22-8C8F-44A2-944F-AEDAF650E7C2Q35136728-53D1B2A5-5EE1-41DA-9BD6-D38D284BF46BQ35684358-822C18C2-BF30-41C4-ABBF-2E0E81F000C8Q35826151-BE1E580D-2620-469C-9DAD-AF0A0ABC02C5Q35853209-5889F3FF-C980-4E2A-9F35-790EED0ECA2CQ36212795-64FE0813-171A-493C-88FD-C426EB453D56Q36223650-354A871B-FBE9-49B0-9CFE-31D99A700286Q36664563-9132B773-BCB6-4E14-AAC9-DA6C030DF4BFQ36803735-092EB97E-DA72-4F5D-9FEF-3D9BA2DD02E6Q36960355-B3114BE5-CAA5-4DCD-9712-9996935E32C6Q36965917-F1706EE0-87F4-4FAE-AFE7-D045E3FFA3E6Q37154788-B920E7FB-8449-4E78-97AC-0EB092CBDBF5Q37189412-225EEADE-972D-4772-9655-2CBC956788DDQ37265168-79E878D3-E2AB-40B5-9AD1-2BAB5AC728CCQ37283464-79FA9523-5732-4E87-A2A3-EDFFAEE25166Q37293908-EDCC2152-4A80-4452-AC41-D3386035121CQ37778062-28342DA6-B118-4527-B1EC-FEF5DC6D3578Q37803419-355CDF92-8052-4904-B255-093E46648A4DQ37965547-D0C54FFC-87D9-48A4-92FD-54EB02D0A754Q38029598-39EF88D9-9AA8-4F0A-A32C-BB45B37515F5Q38049628-77EE5253-5F68-472C-81AE-B03D3F6CAA1FQ38103059-D699ACCD-C30A-4387-BEF9-38DFAE4BE312
P2860
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Brain sphingosine-1-phosphate ...... eatment of multiple sclerosis.
@en
type
label
Brain sphingosine-1-phosphate ...... eatment of multiple sclerosis.
@en
prefLabel
Brain sphingosine-1-phosphate ...... eatment of multiple sclerosis.
@en
P2093
P1476
Brain sphingosine-1-phosphate ...... eatment of multiple sclerosis.
@en
P2093
Florian Mullershausen
Graeme Bilbe
Henri Mattes
Rainer R Kuhn
P356
10.1016/J.PHARMTHERA.2007.08.005
P577
2007-09-08T00:00:00Z